Abstract
McKesson Corporation will report fiscal second quarter 2027 results on November 4, 2026, Post-Mkt; investors are watching whether top-line growth near 5.51% year over year and accelerating adjusted EPS can be sustained alongside integration momentum from announced transactions and clarity on GLP-1 reimbursement dynamics.
Market Forecast
Consensus for the current fiscal quarter points to revenue of 109.88 billion US dollars, up 5.51% year over year, with adjusted EPS of 10.70, up 18.41% year over year; EBIT is projected at 1.70 billion US dollars, up 14.94% year over year. Forecasts for gross margin and net margin were not disclosed.
The core distribution engine is expected to remain supported by specialty-drug volume and biosimilar adoption, reinforcing stable throughput against modest pricing friction. The most promising segment remains Oncology and Multispecialty, which delivered 14.22 billion US dollars last quarter and is poised for incremental growth on pending acquisitions and service expansion; year-over-year segment growth was not disclosed.
Last Quarter Review
In fiscal first quarter 2027, McKesson Corporation posted revenue of 105.38 billion US dollars, a gross profit margin of 3.50%, GAAP net income attributable to shareholders of 614.00 million US dollars, a net profit margin of 0.58%, and adjusted EPS of 9.93, up 20.22% year over year.
A notable highlight was operating leverage: EBIT reached 1.59 billion US dollars, up 16.69% year over year, and management raised its full-year adjusted EPS outlook to a higher range, signaling confidence in execution and mix.
By business line last quarter, North American Pharmaceuticals contributed 86.77 billion US dollars, Oncology and Multispecialty 14.22 billion US dollars, Medical-Surgical Distribution and Services 2.82 billion US dollars, and Technology Solutions – Products and Services 1.57 billion US dollars; year-over-year segment growth was not disclosed.
Current Quarter Outlook
U.S. Pharmaceutical distribution
For fiscal second quarter 2027, McKesson Corporation’s North American distribution engine should continue to be anchored by specialty therapies, which now account for a growing share of channel volume. The company’s revenue model historically captures underlying market growth with pass-through pricing and scale efficiencies, and consensus expects top-line expansion of 5.51% year over year to 109.88 billion US dollars. Product mix remains a central driver: as biosimilars penetrate more categories, volume uplift and customer retention can offset pricing normalization and reimbursement drag, supporting EBIT growth expectations of 14.94% year over year to 1.70 billion US dollars.
GLP-1 utilization remains an important undercurrent for the quarter’s flow through the channel and associated services. While employer plan coverage shows signs of tightening in certain markets, script volumes continue to be supported by strong patient demand and broader access programs. Given the low-single-digit gross margin structure in distribution, margin stability hinges on disciplined purchasing, inventory turns, and fee-for-service economics rather than unit pricing alone; the prior quarter’s gross margin of 3.50% provides a reference point for investors, though formal margin guidance for the current quarter was not disclosed.
On balance, the setup suggests steady revenue conversion from high-cost specialty therapies and biosimilar adoption, with limited margin volatility if working capital and fee dynamics remain well controlled. Watch commentary around biosimilar uptake rates and any incremental contracting wins with large provider systems, which could influence the cadence of revenue capture across the remainder of the fiscal year.
Oncology and Multispecialty services
The Oncology and Multispecialty segment, which generated 14.22 billion US dollars in the prior quarter, is positioned as the company’s near-term growth lever given a strong pipeline of value-added services and announced transaction activity. Management has signed a definitive agreement to acquire Precision Medicine Group for roughly 2.25 billion US dollars; upon closing, this business is expected to be consolidated into Oncology and Multispecialty. The combination enhances trial execution, biomarker-led development capabilities, and commercialization services, tying together clinical research and practice-facing solutions under one umbrella.
Momentum is also supported by a definitive agreement with a private equity partner to purchase Option Care Health for an enterprise value of approximately 5.80 billion US dollars, where McKesson would hold a minority stake. The home-infusion angle complements oncology and complex care pathways by extending reach into sites of care with rising therapy complexity and supportive-care needs. While the revenue impact in the quarter under review is limited by deal timing and customary closing conditions, investors should expect management’s update to center on integration priorities, cross-sell opportunities, and the medium-term revenue synergy roadmap.
In the near term, a favorable case mix within community oncology, deeper ties with biopharma sponsors, and the expansion of clinical and commercialization offerings can collectively sustain above-company growth rates within this segment. Items to monitor on the call include patient enrollment trends, new service launches, and early pipeline conversion tied to Precision Medicine Group’s clinical and analytics platforms.
Items most likely to drive the stock this quarter
Guidance and deal updates are likely to be the principal stock drivers on November 4, 2026. Following last quarter’s beat and a raised full-year adjusted EPS outlook, investors will look for a reaffirmation or upward revision consistent with consensus-adjusted EPS of 10.70 this quarter and the path toward the updated full-year range. Any commentary bridging fiscal second quarter performance to full-year assumptions on volumes, biosimilar adoption, and specialty-drug throughput will be closely parsed.
Policy and payer dynamics around GLP-1 coverage represent the key variable for the Technology Solutions and services ecosystem. Some employers have reduced GLP-1 coverage, which can temper prior-authorization volumes in the near term; there is also an offsetting tailwind from Medicare’s GLP-1 Bridge program enrollment that can support income in the prescription technology solutions stack. Management’s discussion of net effects on transaction and service volumes in the quarter, alongside mitigation levers, will inform the durability of high-teens EPS growth currently reflected in consensus.
Event headlines and operational execution also matter. The company disclosed a cybersecurity incident on August 25, 2026; investors will seek reassurance on remediation, continuity, and whether the incident has had any measurable financial impact. Additionally, the timing, regulatory pathway, and integration plans for the Precision Medicine Group acquisition and the Option Care Health transaction will influence the multi-quarter earnings power narrative. Finally, capital allocation cadence remains important: with the quarterly dividend maintained at 0.94 dollars per share, commentary on share repurchases and reinvestment priorities could frame return expectations for the second half of fiscal 2027.
Analyst Opinions
Across the collected views this year through October 28, 2026, roughly 80% of opinions are bullish versus 20% bearish/neutral; the majority stance is bullish, and we present that view. Multiple well-known institutions have reiterated positive ratings and raised price targets, emphasizing balanced growth in distribution, expanding oncology services, and incremental optionality from acquisitions and partnerships.
Morgan Stanley’s Erin Wright reiterated a Buy rating and maintained a 977 dollars price target, highlighting how a strategic stake associated with Option Care Health strengthens McKesson Corporation’s home-infusion strategy and deepens the company’s presence in complex therapies. The analyst’s constructive stance aligns with the thesis that expanding sites-of-care capabilities can improve patient access while bolstering the stickiness of provider relationships and the company’s broader services portfolio. This line of thinking supports the argument that oncology and complex care adjacencies will add to medium-term EBIT growth beyond what consensus currently embeds for core distribution.
Bank of America’s Allen Lutz reaffirmed a Buy rating and a 1,050 dollars price target after the announcement to acquire Precision Medicine Group, framing the deal as an acceleration of the oncology platform. The logic is that integrating clinical development support, biomarker testing, and commercialization solutions creates a more unified offering for biopharma sponsors and oncology practices. This should translate into better customer conversion, deeper engagement across the drug lifecycle, and a pathway for steadier, higher-margin service revenues. In the near term, Bank of America expects the core distribution engine to continue performing, with upside optionality from services and technology as the acquisition pipeline matures.
UBS lifted its price target to 1,200 dollars while maintaining a Buy rating, arguing that the company’s earnings power is being understated relative to the visibility in specialty drug channel growth and the incremental contribution from biosimilars over the next few years. UBS’s view dovetails with consensus forecasts calling for EBIT growth of 14.94% year over year this quarter, supported by consistent execution, stable working capital dynamics, and mix improvements. With adjusted EPS expected to rise 18.41% year over year to 10.70 this quarter, UBS’s framework implies room for continued multiple support if management reaffirms full-year guardrails and articulates a clear integration timeline.
Mizuho, Leerink Partners, Baird, Barclays, and Argus have each raised targets or reiterated Buy/Overweight ratings in recent months, generally pointing to sustained specialty throughput, biosimilar adoption, and services expansion. Mizuho lifted its target to 1,020 dollars, Leerink Partners to 1,070 dollars, Baird to 1,017 dollars, Barclays to 1,000 dollars, and Argus to 970 dollars, reflecting confidence that mid-single-digit revenue growth can translate into high-teens EPS growth through mix, operating discipline, and targeted M&A. The thread running through these bullish previews is that consolidation of oncology services and the home-infusion adjacency can expand the company’s addressable service stack, while not disrupting the core distribution’s steady volume capture.
Counterpoints from sector-perform and hold-rated houses, such as RBC Capital Markets and Wells Fargo, generally center on payer coverage decisions for GLP-1 therapies and their near-term effect on the prescription technology services layer. However, even these notes acknowledge partial offsets from programs like the Medicare GLP-1 Bridge initiative and continued strength in specialty distribution. Given the weight of positive commentary and the series of price-target increases, the consensus narrative into November 4, 2026 remains that revenue growth near 5.51% and adjusted EPS growth near 18.41% can be delivered, with updates on transaction timing and GLP-1 utilization serving as the main swing factors for the stock reaction.
Overall, the bullish camp expects a clean print characterized by 109.88 billion US dollars of revenue, resilient low-single-digit margins consistent with the model, and adjusted EPS around 10.70; clarity on acquisition integration and payer dynamics could serve as catalysts for guidance confidence. In this framework, Oncology and Multispecialty stands out as the most promising vector for medium-term expansion given the Precision Medicine Group acquisition and the strategic alignment with home infusion. Should management’s commentary match these institutional previews, investors may see the constructive stance reflected in sustained target and estimate revisions into the back half of fiscal 2027.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments